Skip to content

Cancer Health Center

Font Size

Adult Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Advanced Unfavorable Hodgkin Lymphoma

Drug combinations described in this section include the following:

  • ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine.
  • BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
  • CEC: cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin.
  • COPP/ABVD: cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, and dacarbazine.
  • MOPP: mechlorethamine, vincristine, procarbazine, and prednisone.
  • MOPP alternating with ABVD: mechlorethamine, vincristine, procarbazine, prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine.
  • MOPP/ABV hybrid: mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, and vinblastine.
  • Stanford V: doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone.

Patients are designated as having advanced unfavorable Hodgkin lymphoma (HL) if they have clinical stage III or stage IV disease and four or more risk factors on the International Prognostic Index for HL, which corresponds to a freedom-from-progression at worse than 70% at 5 years with combination chemotherapy.[1]

Recommended Related to Leukemia & Lymphoma

Understanding Hodgkin Lymphoma -- Diagnosis and Treatment

The diagnosis of Hodgkin lymphoma can only be made by a tissue biopsy -- cutting a tissue sample for examination. If you have an enlarged, painless lymph node that your doctor suspects may be due to Hodgkin lymphoma, tissue will be taken for biopsy or the entire node will be removed. The diagnosis of Hodgkin lymphoma is sometimes confirmed by the presence of a type of cell called a Reed-Sternberg cell. If a biopsy reveals that you do have Hodgkin lymphoma, you may need additional tests to determine...

Read the Understanding Hodgkin Lymphoma -- Diagnosis and Treatment article > >

ABVD therapy for 6 to 8 months is as effective as 12 months of MOPP alternating with ABVD, and both are superior to MOPP alone in terms of failure-free survival (FFS) (50% vs. 36% with a 14-year median follow-up; P = .03).[2,3][Level of evidence: 1iiA] The Intergroup trial comparing ABVD with MOPP/ABV hybrid showed equivalent efficacy in FFS and overall survival (OS), but increased toxic effects in the hybrid arm, especially from second malignancies.[4][Level of evidence: 1iiA]

The German Hodgkin Study Group (GHSG HD9 trial) randomly assigned 1,201 patients with advanced-stage disease to COPP/ABVD, BEACOPP, or to escalated BEACOPP, with most patients receiving consolidative radiation therapy to sites of initial bulky disease (≥5 cm).[5] The 10-year OS rates from time of treatment were 75% for COPP/ABVD, 80% for BEACOPP, and 86% for escalated BEACOPP (P = .19 for the comparison of COPP/ABVD with BEACOPP, P = .005 for the comparison of BEACOPP with escalated BEACOPP, and P < .001 for the comparison of COPP/ABVD with increased-dose BEACOPP).[5][Level of evidence: 1iiA] The actuarial rate of secondary acute leukemias 10 years after diagnosis of HL was 0.4% for COPP/ABVD, 1.5% for BEACOPP, and 3.0% for escalated BEACOPP (P = .03).

    1|2|3
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article